The selective ERK inhibitor BVD-523 is active in models of MAPK - - PowerPoint PPT Presentation

▶
the selective erk inhibitor bvd 523 is active in models
SMART_READER_LITE
LIVE PREVIEW

The selective ERK inhibitor BVD-523 is active in models of MAPK - - PowerPoint PPT Presentation

Oct 30, 2022 29 likes •212 views

The selective ERK inhibitor BVD-523 is active in models of MAPK pathway-dependent cancers, including those with intrinsic and acquired drug resistance Ursula Germann 1 , Brinley Furey 2 , Jeff Roix 3 , William Markland 2 , Russell Hoover 2 , Alex

slide-1
SLIDE 1

The selective ERK inhibitor BVD-523 is active in models of MAPK pathway-dependent cancers, including those with intrinsic and acquired drug resistance

Ursula Germann1, Brinley Furey2, Jeff Roix3, William Markland2, Russell Hoover2, Alex Aronov2, Michael Hale4, Guanjing Chen5, Gabriel Martinez-Botella6, Rossitza Alargova7, Bin Fan8, David Sorrell9, Kay Meshaw10, Paul Shapiro11, Michael J. Wick12, Cyril Benes13, Mathew Garnett14, Gary DeCrescenzo15, Mark Namchuk16, Saurabh Saha15, Dean J. Welsch15.

1OnKognos Scientific Consulting and Services, MA; 2Vertex Pharmaceuticals, MA; 3Phoremost, United Kingdom; 4AstraZeneca, MA; 5Novartis, MA; 6Sage Therapeutics, MA; 7Blend Therapeutics, MA; 8AVEO Pharmaceuticals, MA; 9Horizon Discovery, Plc, United Kingdom; 10Charles River Discovery Research Services, NC; 11University of Maryland,

Baltimore, MD; 12South Texas Accelerated Research Therapeutics, TX; 13Massachusetts General Hospital, Harvard Medical School, MA; 14Wellcome Trust Sanger Institute, United Kingdom; 15BioMed Valley Discoveries, MO; 16Alkermes, MA.

AA AACR ¡An CR ¡Annual ¡M ¡Mee+ ee+ng, ¡Ap ¡April ¡1 ¡18-­‑2

  • ­‑22, ¡2

¡2015 Se Sessio ssion ¡ n ¡Title itle: ¡ : ¡Ex Explo ploi+ng ¡ i+ng ¡the the ¡ ¡MA MAPK PK ¡ ¡Path thway ¡ y ¡in ¡ in ¡Canc ancer r Session ¡ ¡Category: ¡ ¡Experime mental ¡ ¡and ¡ ¡Molecular ¡ ¡Therapeu+cs

Contact: Dean Welsch (dwelsch@biomed-valley.com)

slide-2
SLIDE 2

2

Disclosure Information

AACR Annual Meeting 2015

  • Dr. Dean J. Welsch

I have the following financial relationship to disclose: Employee of BioMed Valley Discoveries I will not discuss off label use and/or investigational use in my presentation

slide-3
SLIDE 3

3

Mechanistic Background & Therapeutic Opportunity

RTKs RAS RAF MEK ERK RSK dabrafenib vemurafenib trametinib

  • MAPK pathway mutations causally drive many cancers
  • 3 MAPK drugs are approved but limited by intrinsic and

acquired resistance

  • ERK inhibition has the potential to overcome or avoid

resistance from upstream mutations

BVD-523

slide-4
SLIDE 4

4

BVD-523 Executive Summary

  • Highly potent, selective and reversible ATP-

competitive ERK1 and ERK2 inhibitor

  • Tumor growth regression in BRAF- and KRAS-

mutant xenograft models

  • Single agent inhibition of a patient-derived

xenograft cross-resistant to BRAFi and MEKi

  • Phase 1 dose escalation completed with

expansion cohorts in progress

slide-5
SLIDE 5

5

BVD-523 (ulixertinib): A Potent & Selective ERK Inhibitor

Highly potent

  • ERK1 Ki < 300 pM
  • ERK2 Ki = 40 pM

Highly selective

  • > 1,000-fold vs CDK1, CDK2, CDK5, CDK6, GSK3b
  • > 10,000-fold vs 70 other kinases

BVD-523

slide-6
SLIDE 6

6

BVD-523 Preferential Activity in Cells with MAPK Pathway Mutations 1 4 7 10 13 16 19 22 25 28 31 34 37 40 43 46 49 52 3 6 9 12 15 18 21 24 27 30 33 36 39 42 45 48 51 54 57 60 63 66 69 72 75

0.01 0.10 1 10 100 Proliferation IC50 [uM]

MAPK mutant MAPK WT

MGH/Wellcome Genomics of Drug Sensitivity in Cancer Panel

MAPK mut. MAPK wt

slide-7
SLIDE 7

7

BVD-523 Mechanism of Action and Enzyme Binding

0 . 0 1 0 . 1 1 1 0 3 6 9 1 2 1 5 B V D - 5 2 3 ( µ M ) D D T m ( K ) E R K 2 p p E R K 2 p 3 8 a

Enzyme: BVD-523 Binding ERK2 ppERK2 p38α

BVD-523

RTKs RAS RAF MEK ERK RSK RSK1/2

p*T359/S363

MEK1/2

p*S217/S221

ERK1/2

p*T202/Y204

BVD-523 (uM) 0.5 2 RKO (BRAF V600E) Colorectal Cancer Cell Line Mechanism of Action

Differential Scanning Fluorimetry

slide-8
SLIDE 8

8

BVD-523 Anti-tumor Activity in Multiple In Vivo Cancer Models

  • Single agent activity in xenografts with
  • ­‑ BRAF mutation (Colo205 CRC, A375 Mel)
  • ­‑ RAS mutation (MiaPaCa2 Panc)
  • At least additive with other MAPK inhibitors

BVD-523 Tumor Growth Inhibition in Colo205 Xenograft

Mean Tumor Volume (mm3 + SEM) Days Following Tumor Cell Implantation

Vehicle 50 mpk/day 100 mpk/day 150 mpk/day

A

slide-9
SLIDE 9

9

Response Correlates with Tumor PK and Dose

ppERK/Total ERK (%) [BVD-523]tumor (ng/mL) Time Post Dose (hrs) 100 mpk, P.O.

pERK Levels Correlate with Tumor PK - Timecourse

B

1 3 8 16 24

pERK IHC

ppERK/Total ERK (%)

pERK Levels Correlate with Tumor PK-Dose

8 hr post-dose

C

Dose (mpk, P.O.)

25 50 75 100

slide-10
SLIDE 10

10

RSK1/2 Phosphorylation as a BVD-523 Activity Clinical Biomarker

p*T359/S363

RSK1/2 is a substrate for ERK phosphorylation

Total pRSK1/2

DMSO BVD523 Vemurafenib Dabrafenib Trametinib 0.5µM 2µM

BVD-523 inhibits RSK1/2 phosphorylation using an ex vivo human whole blood assay

RSK1/2 p*S380

% of Control 10 Human PBMC Donors RKO BRAF V600E CRC Cells

BVD-523

RTKs RAS RAF MEK ERK RSK

slide-11
SLIDE 11

11

RSK1/2 Phosphorylation as a Clinical Biomarker for BVD-523 Activity

BVD-523 inhibits ERK activity following

  • ral dosing in canine GLP tox study

Dose (mg/kg, BID) ERK Inhibition (%) BVD-523 Conc. (uM) Vehicle 2 53 0.23 5 64 0.92 15 94 3.2

  • Human and canine whole blood ERK activity assays established
  • BVD-523 demonstrated significant ERK inhibition with chronic oral

dosing in canine GLP toxicity study at tolerated doses, exposures

  • ERK activity assay supporting clinical studies
slide-12
SLIDE 12

12

BVD-523 Effective in Models of Acquired Resistance to BRAF and MEK Inhibitors

Vemurafenib Trametinib BVD-523

RKO parental

BVD-523 potency retained in cells cross-resistant to BRAFi & MEKi

Cell Line Proliferation IC50 (nM) Dabrafenib Trametinib BVD-523 Paclitaxel Parental 2.1 0.2 129 1.9 BRAFi + MEKi- Resistant 17.9 2.7 323 4.7 Fold Increase 8.5 13.5 2.5 2.5

BVD-523 sensitivity retained in A375 cells cultured to acquire resistance to BRAFi + MEKi combination

MEK1 Q56P

slide-13
SLIDE 13

13

BVD-523 Effective in Xenografts Derived from a Patient Who Progressed on BRAF Inhibitor BVD-523 sensitivity in patient-derived xenograft model

Intrinsic BRAF Sensitivity

BRAFi ¡& ¡MEKi ¡Insensi/vity ¡ ¡ ¡ ¡ ¡ ¡ ¡ ¡ ¡ ¡ ¡ ¡ ¡ ¡ ¡ ¡ ¡ ¡ ¡ ¡ ¡ ¡ ¡ ¡ ¡ ¡ ¡ ¡ ¡ ¡ERKi ¡Sensi/vity ¡

500 1000 1500 7 14 21 Day

Baseline Post-Progression

Tumors that escape BRAFi and MEKi may remain sensitive to ERKi ¡

Tumor Volume (mm3)

Intrinsic ¡BRAFi ¡Sensi/vity ¡

Vehicle Vemurafenib Vehicle Dabrafenib BVD-523 BVD-523 + Dabrafenib Vehicle Trametinib Vemurafenib

slide-14
SLIDE 14

14

BVD-523 IND Enabling Studies – Summary of Findings

Safety Pharmacology

  • No significant interaction in in vitro screens

against 65 receptors, transporters, and ion channels

  • Exhibited no significant genetic toxicology risks in

reverse mutation and micronucleus assays

  • Inhibits the hERG current (IC50 3.4 uM)
  • Dog Purkinje fiber assays revealed no significant

effects up to 10 ug/mL

Metabolism

  • Recombinant human CYP1A2, CYP2C9,

CYP2C19, CYP2D6, and CYP3A4 capable of metabolizing BVD-523

  • Metabolism predominantly via oxidation and de-

alkylation

  • Metabolic profile of BVD-523 across mouse, rat,

dog, and human liver microsomes and hepatocytes very similar (monkey was unique in its metabolic profile)

  • Rat & dog identified as appropriate species for

toxicological evaluation

GLP Toxicity Studies

  • No CV findings observed following 28 days of

dosing with BVD-523

  • 28-day studies, with reversal arms, conducted at

doses ranging from 25-100 mg/kg/day and 4-30 mg/kg/day in rat and dog, respectively

Target Tissue Toxicities

  • Findings are dose-dependent, and at least

partially reversible

  • Rat: tissue mineralization, skin lesions/rash
  • Dog: gastrointestinal
  • All toxicities consistent with MAPK pathway

inhibitors, further demonstrating the exquisite selectivity of BVD-523

Starting Dose Justification

  • Rat identified as most sensitive species
  • Supported first-in-human starting dose of

10 mg, BID

slide-15
SLIDE 15

15

Current Status

BVD-523 Clinical Development Plan – Ongoing Studies

Group 1: BRAF V600E/K mutant melanoma, inhibitor naive Group 2: BRAF non-V600E/K mutant melanoma, inhibitor naive Group 3: BRAF mutant melanoma, progressed/refractory to BRAFi &/or MEKi Group 4: NRAS mutant melanoma, inhibitor naive Group 5: MEK mutant cancers, inhibitor naive Group 6: BRAF mutant NSCLC, inhibitor naive Accelerated Dose Titration (1 pt per cohort) FIH (10 mg, BID) > Grade 2 Related AE Standard “3 + 3” Dose Escalation Solid Tumor RP2D Standard “3 + 3” Dose Escalation AML/MDS RP2D Group 1: AML/MDS w/o RAS mutation Group 2: AML/MDS w/ RAS mutation Advanced Solid Tumor Protocol (NCT01781429) Acute Myelogenous Leukemia

  • r Myelodysplastic Syndromes Protocol

(NCT02296242) Solid Tumor RP2D X 0.5

slide-16
SLIDE 16

16

BVD-523 Clinical Development Plan – Potential Studies

  • BVD-523 + BRAFi, MEKi, or BRAFi & MEKi
  • BVD-523 + BRAFi, MEKi, or BRAFi & MEKi after acquired resistance
  • BVD-523 + non-MAPK pathway targeted agents
  • BVD-523 + immune response modulators
  • BVD-523 + chemotherapeutics
  • BVD-523 + ???

Possible Protocols

slide-17
SLIDE 17

17

BVD-523 Executive Summary

  • Highly potent, selective and reversible ATP-

competitive ERK1 and ERK2 inhibitor

  • Tumor growth regression in BRAF- and KRAS-

mutant xenograft models

  • Single agent inhibition of a patient-derived

xenograft cross-resistant to BRAFi and MEKi

  • Phase 1 dose escalation completed with

expansion cohorts in progress

slide-18
SLIDE 18

The selective ERK inhibitor BVD-523 is active in models of MAPK pathway-dependent cancers, including those with intrinsic and acquired drug resistance

Ursula Germann1, Brinley Furey2, Jeff Roix3, William Markland2, Russell Hoover2, Alex Aronov2, Michael Hale4, Guanjing Chen5, Gabriel Martinez-Botella6, Rossitza Alargova7, Bin Fan8, David Sorrell9, Kay Meshaw10, Paul Shapiro11, Michael J. Wick12, Cyril Benes13, Mathew Garnett14, Gary DeCrescenzo15, Mark Namchuk16, Saurabh Saha15, Dean J. Welsch15.

1OnKognos Scientific Consulting and Services, MA; 2Vertex Pharmaceuticals, MA; 3Phoremost, United Kingdom; 4AstraZeneca, MA; 5Novartis, MA; 6Sage Therapeutics, MA; 7Blend Therapeutics, MA; 8AVEO Pharmaceuticals, MA; 9Horizon Discovery, Plc, United Kingdom; 10Charles River Discovery Research Services, NC; 11University of Maryland,

Baltimore, MD; 12South Texas Accelerated Research Therapeutics, TX; 13Massachusetts General Hospital, Harvard Medical School, MA; 14Wellcome Trust Sanger Institute, United Kingdom; 15BioMed Valley Discoveries, MO; 16Alkermes, MA.

AA AACR ¡An CR ¡Annual ¡M ¡Mee+ ee+ng, ¡Ap ¡April ¡1 ¡18-­‑2

  • ­‑22, ¡2

¡2015 Se Sessio ssion ¡ n ¡Title itle: ¡ : ¡Ex Explo ploi+ng ¡ i+ng ¡the the ¡ ¡MA MAPK PK ¡ ¡Path thway ¡ y ¡in ¡ in ¡Canc ancer r Session ¡ ¡Category: ¡ ¡Experime mental ¡ ¡and ¡ ¡Molecular ¡ ¡Therapeu+cs

Contact: Dean Welsch (dwelsch@biomed-valley.com)